 |
市場調查報告書
商品編碼
1422743
全球生長激素缺乏症市場，預測（~2027 年）Growth Hormone Deficiency Market Research Report Forecast to 2027 |
||||||
價格
在預測期內，生長激素缺乏症市場規模預計將以 4.19% 的複合年增長率穩定成長。
由於分析技術的進步、正念的擴展和治療選擇的擴大，生長激素缺乏症市場正在經歷顯著增長。 由於人們對生長激素缺乏對健康影響的認識不斷提高以及研發工作的進步，預計該市場將會擴大。
依地區劃分，2022年美洲地區所佔份額最大。 醫療服務框架的建設、機械進步的擴大以及大量進入者的存在等因素促成了這一份額。 另一方面，亞太地區預計將在預測期內呈現最高成長。 這種增長是由於治療方法的進步、研發資產的增加以及生長激素缺乏症的盛行率日益增加。
本報告調查了全球生長激素缺乏症市場，提供了市場的定義和概述，分析了市場成長的各種影響因素、市場規模的趨勢和預測、各個細分市場和地區的細分以及競爭。我們總結了環境、主要公司簡介等
目錄
第 1 章執行摘要
第 2 章市場概述
第 3 章研究方法
第 4 章市場動態
- 促進因素
- 抑制因素
- 機會
- 臨床試驗分析
- 大趨勢
- 宏觀經濟指標
- 法律法規/新的治療方案
- LAGH (LONG ACTING GROWTH HORMONES)
第 5 章市場影響因素分析
- 供應鏈分析
- 波特五力分析
- 新冠肺炎 (COVID-19) 的影響
- 生長激素缺乏症的類型：流行病學數據
第 6 章全球生長激素缺乏症市場：依品牌
- 摘要
- NORDITROPIN
- GENOTROPIN
- HUMATROPE
- SAIZEN
- OMNITROPE
第 7 章全球生長激素缺乏症市場：依應用分類
- 摘要
- 兒童生長激素缺乏症
- 特發性身材矮小
- SGA
- 特納氏症
- 成人生長激素缺乏症
- 普拉德-威利症候群
第 8 章全球生長激素缺乏症市場：依給藥途徑
- 摘要
- 皮下
- 肌肉注射
- 靜脈注射
第 9 章全球生長激素缺乏症市場：依通路劃分
- 摘要
- 醫院藥房
- 零售藥局
- 診所
- 電子商務網站
第 10 章全球生長激素缺乏症市場：按地區
- 摘要
- 北美
- 歐洲
- 亞太地區
- 中東/非洲
- 拉丁美洲
第 11 章競爭態勢
- 摘要
- 全球市佔率分析
- 競爭基準測試
- 主要成長策略
- 主要公司的開發數量
- 主要發展與成長策略
第 12 章公司簡介
- MERCK KGAA
- NOVO NORDISK A/S
- ELI LILY AND COMPANY
- F. HOFFMAN LA ROCHE LTD
- PFIZER, INC.
- NOVARTIS AG
- IPSEN PHARMA
- FERRING PHARMACEUTICALS
- ANKEBIO CO., LTD
- ZHONGSHAN SINOBIOWAY HYGENE BIOMEDICINE CO., LTD
第 13 章附錄
Product Code: MRFR/HC/8950-CR
Market Overview
The Growth Hormone Deficiency Market is anticipated to register a healthy CAGR of 4.19% during the review period.
The growth hormone deficiency market is encountering critical growth driven by headways in analysis, expanding mindfulness, and extending treatment choices. Developing acknowledgment of the effect of growth hormone deficiency on wellbeing, combined with progressing research and improvement endeavors, positions this market for proceeded with extension soon.
The growth of the Growth Hormone Deficiency Market is supposed to be driven by the rising number of people experiencing growth hormone deficiency (GHD), rising mindfulness in regard to the adequacy of GH alongside clinical preliminaries zeroed in on the security and viability of GHD, and the changing way of life alongside the developing predominance of hereditary problems.
As per the distributed article in NCBI in Walk 2017, the assessed commonness of GHD is roughly 2-3 out of 10,000 populaces. GHD is brought about by primary pituitary sickness or cranial illumination and happens with regards to extra elements of hypopituitarism. Pituitary adenomas are reported to cause grown-up beginning GHD followed by craniopharyngiomas, which represents roughly 57% of cases. What's more, adolescence beginning growth hormone deficiency (CO-GHD) is one of the perplexing endocrine circumstances that might have an effect over the course of life, beginning in youth, and going on till adulthood. Most of the CO-GH is reported to be intrinsic. The fundamental co-morbidities and side effects of GHD in grown-ups and kids are heftiness, diabetes mellitus, hypertension, cerebrovascular illnesses, cardiovascular sicknesses, and liver sicknesses. This rising bleakness of GH sickness in the two kids and grown-ups is supposed to drive the growth of the growth hormone deficiency market.
Market Segmentation
Norditropin, Genotropin, Humatrope, Saizen, Omnitrope, and more brands are included in the Growth Hormone Deficiency Market segmentation based on brand.
The market is divided into categories according to the application: prader-willi syndrome, turner syndrome, adult growth hormone deficit, small for gestational age, idiopathic short stature, and others.
The subcutaneous, intramuscular, and intravenous routes of delivery are used to segment the growth hormone deficiency market. Clinics, e-commerce websites, hospital pharmacies, and retail pharmacies make up the market's distribution channels.
Regional Insights
The Americas growth hormone deficiency market represented the biggest market share in 2022. Key elements ascribed to its huge offer incorporate created medical services framework, expanding mechanical headway, and the presence of many market players in the region.
Europe growth hormone deficiency market represented the second-biggest market share because of developing predominance of GHD people, and the rising attention to treatment.
The Asia-Pacific growth hormone deficiency market is supposed to be the quickest developing from 2023 to 2027 because of developing progression in treatment, expanding assets in research exercises, and rising pervasiveness of GHD.
Major Players
Key Companies in the Growth Hormone Deficiency market includes Novo Nordisk A/S (Denmark), Pfizer, Inc. (US), Merck KGaA (Germany), Eli Lily and Company (Netherlands), Novartis AG (Switzerland), Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Ispen Pharma (Switzerland), Ferring Pharmaceuticals (Switzerland), AnkeBio Co., Ltd (China), and Zhongshan Sinobioway Hygene Biomedicine Co., Ltd (China).
TABLE OF CONTENTS
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
- 2.1 DEFINITION
- 2.2 SCOPE OF THE STUDY
- 2.3 RESEARCH OBJECTIVE
- 2.4 MARKET STRUCTURE
- 2.5 ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
- 3.1 DATA MINING
- 3.2 SECONDARY RESEARCH
- 3.3 PRIMARY RESEARCH
- 3.4 BREAKDOWN OF PRIMARY RESPONDENTS
- 3.5 FORECASTING TECHNIQUES
- 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
- 3.6.1 BOTTOM-UP APPROACH
- 3.6.2 TOP-DOWN APPROACH
- 3.7 DATA TRIANGULATION
- 3.8 VALIDATION
4 MARKET DYNAMICS
- 4.1 OVERVIEW
- 4.2 DRIVERS
- 4.2.1 INCREASING INCIDENCE OF GROWTH HORMONE DEFICIENCY
- 4.2.2 RISING NUMBER OF CLINICAL TRIAL FOR GH DEFICIENCY
- 4.2.3 GOVERNMENT INITIATIVES FOR GHD
- 4.2.4 INCREASING NUMBER OF PRODUCT LAUNCH AND STRATEGIC COLLABORATIONS AMONG MARKET PLAYERS
- 4.3 RESTRAINTS
- 4.3.1 HIGH COST OF GHD TREATMENT
- 4.3.2 INCREASING COUNTERFEIT PRODUCTS FOR GHD TREATMENT
- 4.4 OPPORTUNITIES
- 4.4.1 STRONG PIPELINE OF HORMONAL DRUGS AND EASY AVAILABILITY OF PHARMA DRUGS ON E-COMMERCE PLATFORMS
- 4.5 CLINICAL TRIALS ANALYSIS
- 4.6 MEGATRENDS
- 4.6.1 ADVENT OF LONG-ACTING RECOMBINANT HUMAN GROWTH HORMONE (RHGH)
- 4.6.2 USE OF HGH AS PERFORMANCE ENHANCERS AND ANTI-AGING AGENTS
- 4.6.3 PRODUCTS UNDER DEVELOPMENT
- 4.7 MACROECONOMIC INDICATORS
- 4.8 GOVERNMENT REGULATIONS AND NEW TREATMENT SCHEMES
- 4.9 LONG ACTING GROWTH HORMONES (LAGH)
- 4.9.1 OVERVIEW
- 4.9.2 DEVELOPMENT
- 4.9.3 UPCOMING PRODUCTS
- 4.9.4 TRENDS
5 MARKET FACTOR ANALYSIS
- 5.1 SUPPLY CHAIN ANALYSIS
- 5.1.1 RESEARCH AND DEVELOPMENT
- 5.1.2 MANUFACTURING
- 5.1.3 DISTRIBUTION
- 5.1.4 MARKETING AND SALES
- 5.1.5 POST-SALES MONITORING
- 5.2 PORTER'S FIVE FORCES MODEL
- 5.2.1 THREAT OF NEW ENTRANTS
- 5.2.2 BARGAINING POWER OF SUPPLIERS
- 5.2.3 THREAT OF SUBSTITUTES
- 5.2.4 BARGAINING POWER OF BUYERS
- 5.2.5 RIVALRY
- 5.3 IMPACT OF COVID-19
- 5.3.1 OVERVIEW
- 5.3.2 IMPACT ON SUPPLY CHAIN
- 5.3.3 IMPACT ON PRODUCTION
- 5.4 EPIDEMIOLOGY DATA ON TYPE OF GROWTH HORMONE DEFICIENCY DISEASES (2022)
6 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY BRAND
- 6.1 OVERVIEW
- 6.2 NORDITROPIN
- 6.3 GENOTROPIN
- 6.4 HUMATROPE
- 6.5 SAIZEN
- 6.6 OMNITROPE
7 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION
- 7.1 OVERVIEW
- 7.2 PAEDIATRIC GROWTH HORMONE DEFICIENCY
- 7.3 IDIOPATHIC SHORT STATURE
- 7.4 SMALL FOR GESTATIONAL AGE
- 7.5 TURNER SYNDROME
- 7.6 ADULT GROWTH HORMONE DEFICIENCY
- 7.7 PRADER-WILLI SYNDROME
8 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION
- 8.1 OVERVIEW
- 8.2 SUBCUTANEOUS
- 8.3 INTRAMUSCULAR
- 8.4 INTRAVENOUS
9 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL
- 9.1 OVERVIEW
- 9.2 HOSPITAL PHARMACIES
- 9.3 RETAIL PHARMACIES
- 9.4 CLINICS
- 9.5 E-COMMERCE WEBSITES
10 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY REGION
- 10.1 OVERVIEW
- 10.2 AMERICAS
- 10.2.1 NORTH AMERICA
- 10.2.1.1 US
- 10.2.1.2 CANADA
- 10.2.2 LATIN AMERICA
- 10.2.1 NORTH AMERICA
- 10.3 EUROPE
- 10.3.1 WESTERN EUROPE
- 10.3.1.1 GERMANY
- 10.3.1.2 FRANCE
- 10.3.1.3 UK
- 10.3.1.4 ITALY
- 10.3.1.5 SPAIN
- 10.3.1.6 REST OF WESTERN EUROPE
- 10.3.2 EASTERN EUROPE
- 10.3.1 WESTERN EUROPE
- 10.4 ASIA-PACIFIC
- 10.4.1 JAPAN
- 10.4.2 CHINA
- 10.4.3 INDIA
- 10.4.4 AUSTRALIA
- 10.4.5 SOUTH KOREA
- 10.4.6 REST OF ASIA-PACIFIC
- 10.5 MIDDLE EAST AND AFRICA
- 10.5.1 MIDDLE EAST
- 10.5.2 AFRICA
11 COMPETITIVE LANDSCAPE
- 11.1 OVERVIEW
- 11.2 GLOBAL GROWTH HORMONE DEFICIENCY MARKET SHARE ANALYSIS (2019)
- 11.3 COMPETITIVE BENCHMARKING
- 11.4 MAJOR GROWTH STRATEGIES IN THE GLOBAL GROWTH HORMONE DEFICIENCY MARKET
- 11.5 THE LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL GROWTH HORMONE DEFICIENCY MARKET
- 11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 11.6.1 EXPANSION
- 11.6.2 PRODUCT APPROVAL/FDA APPROVAL
12 COMPANY PROFILES
- 12.1 MERCK KGAA
- 12.1.1 COMPANY OVERVIEW
- 12.1.2 FINANCIAL OVERVIEW
- 12.1.3 PRODUCTS/SERVICES OFFERED
- 12.1.4 KEY DEVELOPMENTS
- 12.1.5 SWOT ANALYSIS
- 12.1.6 KEY STRATEGIES
- 12.2 NOVO NORDISK A/S
- 12.2.1 COMPANY OVERVIEW
- 12.2.2 FINANCIAL OVERVIEW
- 12.2.3 PRODUCTS/SERVICES OFFERED
- 12.2.4 KEY DEVELOPMENTS
- 12.2.5 SWOT ANALYSIS
- 12.2.6 KEY STRATEGIES
- 12.3 ELI LILY AND COMPANY
- 12.3.1 COMPANY OVERVIEW
- 12.3.2 FINANCIAL OVERVIEW
- 12.3.3 PRODUCTS/SERVICES OFFERED
- 12.3.4 KEY DEVELOPMENTS
- 12.3.5 SWOT ANALYSIS
- 12.3.6 KEY STRATEGIES
- 12.4 F. HOFFMAN LA ROCHE LTD
- 12.4.1 COMPANY OVERVIEW
- 12.4.2 FINANCIAL OVERVIEW
- 12.4.3 PRODUCTS/SERVICES OFFERED
- 12.4.4 KEY DEVELOPMENTS
- 12.4.5 SWOT ANALYSIS
- 12.4.6 KEY STRATEGIES
- 12.5 PFIZER, INC.
- 12.5.1 COMPANY OVERVIEW
- 12.5.2 FINANCIAL OVERVIEW
- 12.5.3 PRODUCTS/SERVICES OFFERED
- 12.5.4 KEY DEVELOPMENTS
- 12.5.5 SWOT ANALYSIS
- 12.5.6 KEY STRATEGIES
- 12.6 NOVARTIS AG
- 12.6.1 COMPANY OVERVIEW
- 12.6.2 FINANCIAL OVERVIEW
- 12.6.3 PRODUCTS/SERVICES OFFERED
- 12.6.4 KEY DEVELOPMENTS
- 12.6.5 SWOT ANALYSIS
- 12.6.6 KEY STRATEGIES
- 12.7 IPSEN PHARMA
- 12.7.1 COMPANY OVERVIEW
- 12.7.2 FINANCIAL OVERVIEW
- 12.7.3 PRODUCTS/SERVICES OFFERED
- 12.7.4 KEY DEVELOPMENTS
- 12.7.5 SWOT ANALYSIS
- 12.7.6 KEY STRATEGIES
- 12.8 FERRING PHARMACEUTICALS
- 12.8.1 COMPANY OVERVIEW
- 12.8.2 FINANCIAL OVERVIEW
- 12.8.3 PRODUCTS/SERVICES OFFERED
- 12.8.4 KEY DEVELOPMENTS
- 12.8.5 SWOT ANALYSIS
- 12.8.6 KEY STRATEGIES
- 12.9 ANKEBIO CO., LTD
- 12.9.1 COMPANY OVERVIEW
- 12.9.2 FINANCIAL OVERVIEW
- 12.9.3 PRODUCTS/SERVICES OFFERED
- 12.9.4 KEY DEVELOPMENTS
- 12.9.5 SWOT ANALYSIS
- 12.9.6 KEY STRATEGIES
- 12.10 ZHONGSHAN SINOBIOWAY HYGENE BIOMEDICINE CO., LTD
- 12.10.1 COMPANY OVERVIEW
- 12.10.2 FINANCIAL OVERVIEW
- 12.10.3 PRODUCTS/SERVICES OFFERED
- 12.10.4 KEY DEVELOPMENTS
- 12.10.5 SWOT ANALYSIS
- 12.10.6 KEY STRATEGIES
13 APPENDIX
- 13.1 REFERENCES
- 13.2 RELATED REPORTS
LIST OF TABLES
- TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
- TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
- TABLE 3 CLINICAL TRIALS OVERVIEW
- TABLE 4 TREATMENT WITH GROWTH HORMONE AND TERMS OF REIMBURSEMENT IN EUROPEAN COUNTRIES
- TABLE 5 COUNTRIES OVERVIEW
- TABLE 6 SUMMARY OF LAGH PREPARATION BASED ON CLASS
- TABLE 7 WORLDWIDE EPIDEMIOLOGY DATA
- TABLE 8 US: EPIDEMIOLOGY DATA
- TABLE 9 UK: EPIDEMIOLOGY DATA
- TABLE 10 ITALY: EPIDEMIOLOGY DATA
- TABLE 11 GERMANY: EPIDEMIOLOGY DATA
- TABLE 12 SPAIN: EPIDEMIOLOGY DATA
- TABLE 13 FRANCE: EPIDEMIOLOGY DATA
- TABLE 14 JAPAN: EPIDEMIOLOGY DATA
- TABLE 15 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)
- TABLE 16 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR NORDITROPIN, BY REGION, 2022-2027 (USD MILLION)
- TABLE 17 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR GENOTROPIN, BY REGION, 2019-2027 (USD MILLION)
- TABLE 18 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR HUMATROPE, BY REGION, 2019-2027 (USD MILLION)
- TABLE 19 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR SAIZEN, BY REGION, 2019-2027 (USD MILLION)
- TABLE 20 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR OMNITROPE, BY REGION, 2019-2027 (USD MILLION)
- TABLE 21 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2027 (USD MILLION)
- TABLE 22 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR PAEDIATRIC GROWTH HORMONE DEFICIENCY, BY REGION, 2019-2027 (USD MILLION)
- TABLE 23 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR IDIOPATHIC SHORT STATURE, BY REGION, 2019-2027 (USD MILLION)
- TABLE 24 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR SMALL FOR GESTATIONAL AGE, BY REGION, 2019-2027 (USD MILLION)
- TABLE 25 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR TURNER SYNDROME, BY REGION, 2019-2027 (USD MILLION)
- TABLE 26 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR ADULT GROWTH HORMONE DEFICIENCY, BY REGION, 2019-2027 (USD MILLION)
- TABLE 27 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR PRADER-WILLI SYNDROME, BY REGION, 2019-2027 (USD MILLION)
- TABLE 28 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)
- TABLE 29 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR SUBCUTANEOUS, BY REGION, 2022-2027 (USD MILLION)
- TABLE 30 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR INTRAMUSCULAR, BY REGION, 2019-2027 (USD MILLION)
- TABLE 31 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR INTRAVENOUS, BY REGION, 2019-2027 (USD MILLION)
- TABLE 32 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
- TABLE 33 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2019-2027 (USD MILLION)
- TABLE 34 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR RETAIL PHARMACIES, BY REGION, 2019-2027 (USD MILLION)
- TABLE 35 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR CLINICS, BY REGION, 2019-2027 (USD MILLION)
- TABLE 36 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR E-COMMERCE WEBSITES, BY REGION, 2019-2027 (USD MILLION)
- TABLE 37 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY REGION, 2019-2027 (USD MILLION)
- TABLE 38 AMERICAS: GROWTH HORMONE DEFICIENCY MARKET, BY REGION, 2019-2027 (USD MILLION)
- TABLE 39 AMERICAS: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)
- TABLE 40 AMERICAS: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2027 (USD MILLION)
- TABLE 41 AMERICAS: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)
- TABLE 42 AMERICAS: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
- TABLE 43 NORTH AMERICA: GROWTH HORMONE DEFICIENCY MARKET, BY COUNTRY, 2019-2027 (USD MILLION)
- TABLE 44 NORTH AMERICA: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)
- TABLE 45 NORTH AMERICA: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2027 (USD MILLION)
- TABLE 46 NORTH AMERICA: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)
- TABLE 47 NORTH AMERICA: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
- TABLE 48 US: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)
- TABLE 49 US: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2027 (USD MILLION)
- TABLE 50 US: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)
- TABLE 51 US: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
- TABLE 52 CANADA: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)
- TABLE 53 CANADA: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2027 (USD MILLION)
- TABLE 54 CANADA: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2027 (USD MILLION)
- TABLE 55 CANADA: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2017-2027 (USD MILLION)
- TABLE 56 LATIN AMERICA: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)
- TABLE 57 LATIN AMERICA: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2027 (USD MILLION)
- TABLE 58 LATIN AMERICA: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)
- TABLE 59 LATIN AMERICA: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
- TABLE 60 EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY REGION, 2019-2027 (USD MILLION)
- TABLE 61 EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)
- TABLE 62 EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2027 (USD MILLION)
- TABLE 63 EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2027 (USD MILLION)
- TABLE 64 EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
- TABLE 65 WESTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY COUNTRY, 2019-2027 (USD MILLION)
- TABLE 66 WESTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)
- TABLE 67 WESTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2022-2027 (USD MILLION)
- TABLE 68 WESTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)
- TABLE 69 WESTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
- TABLE 70 GERMANY: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)
- TABLE 71 GERMANY: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2027 (USD MILLION)
- TABLE 72 GERMANY: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)
- TABLE 73 GERMANY: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
- TABLE 74 FRANCE: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)
- TABLE 75 FRANCE: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2027 (USD MILLION)
- TABLE 76 FRANCE: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2027 (USD MILLION)
- TABLE 77 FRANCE: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
- TABLE 78 UK: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)
- TABLE 79 UK: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2027 (USD MILLION)
- TABLE 80 UK: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2027 (USD MILLION)
- TABLE 81 UK: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
- TABLE 82 ITALY: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)
- TABLE 83 ITALY: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2027 (USD MILLION)
- TABLE 84 ITALY: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)
- TABLE 85 ITALY: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
- TABLE 86 SPAIN: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)
- TABLE 87 SPAIN: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2027 (USD MILLION)
- TABLE 88 SPAIN: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)
- TABLE 89 SPAIN: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
- TABLE 90 REST OF WESTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)
- TABLE 91 REST OF WESTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2027 (USD MILLION)
- TABLE 92 REST OF WESTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)
- TABLE 93 REST OF WESTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
- TABLE 94 EASTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)
- TABLE 95 EASTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2027 (USD MILLION)
- TABLE 96 EASTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)
- TABLE 97 EASTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
- TABLE 98 ASIA-PACIFIC: GROWTH HORMONE DEFICIENCY MARKET, BY COUNTRY, 2019-2027 (USD MILLION)
- TABLE 99 ASIA-PACIFIC: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)
- TABLE 100 ASIA-PACIFIC: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2027 (USD MILLION)
- TABLE 101 ASIA-PACIFIC: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)
- TABLE 102 ASIA-PACIFIC: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
- TABLE 103 JAPAN: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)
- TABLE 104 JAPAN: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2027 (USD MILLION)
- TABLE 105 JAPAN: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)
- TABLE 106 JAPAN: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
- TABLE 107 CHINA: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)
- TABLE 108 CHINA: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2027 (USD MILLION)
- TABLE 109 CHINA: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)
- TABLE 110 CHINA: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
- TABLE 111 INDIA: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)
- TABLE 112 INDIA: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2027 (USD MILLION)
- TABLE 113 INDIA: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)
- TABLE 114 INDIA: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
- TABLE 115 AUSTRALIA: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)
- TABLE 116 AUSTRALIA: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2027 (USD MILLION)
- TABLE 117 AUSTRALIA: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)
- TABLE 118 AUSTRALIA: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
- TABLE 119 SOUTH KOREA: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)
- TABLE 120 SOUTH KOREA: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2027 (USD MILLION)
- TABLE 121 SOUTH KOREA: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)
- TABLE 122 SOUTH KOREA: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
- TABLE 123 REST OF ASIA-PACIFIC: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)
- TABLE 124 REST OF ASIA-PACIFIC: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2027 (USD MILLION)
- TABLE 125 REST OF ASIA-PACIFIC: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)
- TABLE 126 REST OF ASIA-PACIFIC: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
- TABLE 127 MIDDLE EAST & AFRICA: GROWTH HORMONE DEFICIENCY MARKET, BY REGION, 2019-2027 (USD MILLION)
- TABLE 128 MIDDLE EAST & AFRICA: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)
- TABLE 129 MIDDLE EAST & AFRICA: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2027 (USD MILLION)
- TABLE 130 MIDDLE EAST & AFRICA: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)
- TABLE 131 MIDDLE EAST & AFRICA: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
- TABLE 132 MIDDLE EAST: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)
- TABLE 133 MIDDLE EAST: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2027 (USD MILLION)
- TABLE 134 MIDDLE EAST: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)
- TABLE 135 MIDDLE EAST: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
- TABLE 136 AFRICA: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)
- TABLE 137 AFRICA: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2027 (USD MILLION)
- TABLE 138 AFRICA: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)
- TABLE 139 AFRICA: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
- TABLE 140 THE MOST ACTIVE PLAYER IN THE GLOBAL GROWTH HORMONE DEFICIENCY MARKET
- TABLE 141 EXPANSION
- TABLE 142 PRODUCT APPROVAL/FDA APPROVAL
- TABLE 143 MERCK KGAA: PRODUCTS/SERVICES OFFERED
- TABLE 144 MERCK KGAA: KEY DEVELOPMENTS
- TABLE 145 NOVO NORDISK A/S: PRODUCTS/SERVICES OFFERED
- TABLE 146 NOVO NORDISK A/S: KEY DEVELOPMENT
- TABLE 147 ELI LILY AND COMPANY: PRODUCTS/SERVICES OFFERED
- TABLE 148 F. HOFFMAN LA ROCHE LTD: PRODUCTS/SERVICES OFFERED
- TABLE 149 PFIZER INC.: PRODUCTS/SERVICES OFFERED
- TABLE 150 NOVARTIS AG: PRODUCTS/SERVICES OFFERED
- TABLE 151 IPSEN PHARMA: PRODUCTS/SERVICES OFFERED
- TABLE 152 FERRING PHARMACEUTICALS: PRODUCTS/SERVICES OFFERED
- TABLE 153 FERRING PHARMACEUTICALS: KEY DEVELOPMENT
- TABLE 154 ANKEBIO CO., LTD: PRODUCTS/SERVICES OFFERED
- TABLE 155 ZHONGSHAN SINOBIOWAY HYGENE BIOMEDICINE CO., LTD: PRODUCTS/SERVICES OFFERED
LIST OF FIGURES
- FIGURE 1 MARKET SYNOPSIS 15
- FIGURE 2 GLOBAL GROWTH HORMONE DEFICIENCY MARKET STRUCTURE 16
- FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES 23
- FIGURE 4 MARKET DYNAMICS: GLOBAL GROWTH HORMONE DEFICIENCY MARKET 26
- FIGURE 5 DRIVERS: IMPACT ANALYSIS 28
- FIGURE 6 RESTRAINTS: IMPACT ANALYSIS 29
- FIGURE 7 ONGOING CLINICAL TRIALS PHASES (%) 33
- FIGURE 8 SUPPLY CHAIN ANALYSIS: GLOBAL GROWTH HORMONE DEFICIENCY MARKET 41
- FIGURE 9 PORTER'S FIVE FORCES MODEL 43
- FIGURE 10 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2022 AND 2027 (USD MILLION) 50
- FIGURE 11 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2022 AND 2027 (USD MILLION) 55
- FIGURE 12 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2022 AND 2027 (USD MILLION) 60
- FIGURE 13 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2022 AND 2027 (USD MILLION) 64
- FIGURE 14 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY REGION, 2022 AND 2027 (USD MILLION) 68
- FIGURE 15 AMERICAS: GROWTH HORMONE DEFICIENCY MARKET SHARE, BY REGION, 2022 (%) 69
- FIGURE 16 NORTH AMERICA: GROWTH HORMONE DEFICIENCY MARKET SHARE, BY COUNTRY, 2022 (%) 72
- FIGURE 17 EUROPE: GROWTH HORMONE DEFICIENCY MARKET SHARE, BY REGION, 2022 (%) 81
- FIGURE 18 WESTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET SHARE, BY COUNTRY, 2022 (%) 84
- FIGURE 19 ASIA-PACIFIC: GROWTH HORMONE DEFICIENCY MARKET SHARE, BY COUNTRY, 2022 (%) 101
- FIGURE 20 MIDDLE EAST & AFRICA: GROWTH HORMONE DEFICIENCY MARKET SHARE, BY REGION, 2022 (%) 116
- FIGURE 21 GLOBAL GROWTH HORMONE DEFICIENCY MARKET SHARE ANALYSIS (2022) 123
- FIGURE 22 BENCHMARKING OF MAJOR COMPETITORS 124
- FIGURE 23 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN THE GLOBAL GROWTH HORMONE DEFICIENCY MARKET 125
- FIGURE 24 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, KEY DEVELOPMENTS & GROWTH STRATEGIES (%) 126
- FIGURE 25 MERCK KGAA: FINANCIAL OVERVIEW SNAPSHOT 128
- FIGURE 26 MERCK KGAA: SWOT ANALYSIS 129
- FIGURE 27 NOVO NORDISK A/S: FINANCIAL OVERVIEW SNAPSHOT 131
- FIGURE 28 NOVO NORDISK A/S: SWOT ANALYSIS 132
- FIGURE 29 ELI LILY AND COMPANY: FINANCIAL OVERVIEW SNAPSHOT 135
- FIGURE 30 ELI LILY AND COMPANY: SWOT ANALYSIS 136
- FIGURE 31 F. HOFFMAN LA ROCHE LTD: FINANCIAL OVERVIEW SNAPSHOT 138
- FIGURE 32 F. HOFFMAN LA ROCHE LTD: SWOT ANALYSIS 139
- FIGURE 33 PFIZER, INC.: FINANCIAL OVERVIEW SNAPSHOT 141
- FIGURE 34 PFIZER, INC.: SWOT ANALYSIS 142
- FIGURE 35 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT 144
- FIGURE 36 NOVARTIS AG: SWOT ANALYSIS 145
- FIGURE 37 IPSEN PHARMA: FINANCIAL OVERVIEW SNAPSHOT 147
- FIGURE 38 IPSEN PHARMA: SWOT ANALYSIS 148
- FIGURE 39 FERRING PHARMACEUTICALS: SWOT ANALYSIS 150
- FIGURE 40 ANKEBIO CO., LTD: SWOT ANALYSIS 152
- FIGURE 41 ZHONGSHAN SINOBIOWAY HYGENE BIOMEDICINE CO., LTD: SWOT ANALYSIS 154
